VIR Vir Biotechnology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1706431 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,696.0%
TTM net income YoY63.0%
TTM EPS YoY67.4%
Revenue 3-yr CAGR36.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-69.8%
Net margin-61.0%
FCF margin-46.8%
EBITDA margin-66.1%
Returns
ROE-21.8%
ROA-17.3%
ROIC (approx.)-25.6%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $68.56M | $74.20M | $86.18M | $1.62B | $1.10B |
| Cost of revenue | $26,000 | $845,000 | $2.77M | $146.32M | $65.86M |
| Gross profit | $68.53M | $73.36M | $83.42M | $1.47B | $1.03B |
| R&D expense | $455.97M | $506.50M | $579.72M | $474.65M | $448.01M |
| SG&A expense | $92.07M | $119.03M | $174.44M | $161.76M | $160.79M |
| Operating income | -$479.33M | -$587.16M | -$684.30M | $833.07M | $420.75M |
| Pretax income | -$437.77M | -$523.11M | -$628.19M | $754.28M | $549.80M |
| Income tax | $217,000 | -$1.15M | -$13.08M | $238.44M | $21.22M |
| Net income | -$437.99M | -$521.96M | -$615.06M | $515.84M | $528.58M |
| EBITDA | -$467.65M | -$572.61M | -$664.85M | $839.85M | $426.03M |
| EPS (basic) | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 |
| EPS (diluted) | -3.16 | -3.83 | -4.59 | 3.83 | 3.96 |
| Weighted avg. shares (diluted) | 138.52M | 136.25M | 134.13M | 134.81M | 133.44M |
| Balance sheet | |||||
| Cash & equivalents | $232.19M | $318.69M | $241.58M | $867.97M | $363.42M |
| Short-term investments | $228.75M | $678.05M | $1.27B | $1.52B | $217.18M |
| Receivables | — | — | — | $0 | $773.08M |
| Current assets | $514.08M | $1.04B | $1.59B | $2.52B | $1.56B |
| PP&E, net | $55.62M | $63.18M | $96.02M | $105.61M | $42.83M |
| Goodwill | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M |
| Intangibles | $7.85M | $8.12M | $22.57M | $32.76M | $33.29M |
| Total assets | $1.00B | $1.40B | $1.92B | $2.80B | $1.95B |
| Current liabilities | $92.81M | $119.66M | $175.41M | $511.03M | $341.24M |
| Total liabilities | $237.55M | $248.43M | $328.82M | $724.12M | $522.42M |
| Shareholders' equity | $765.28M | $1.15B | $1.59B | $2.08B | $1.43B |
| Shares outstanding | 139.47M | 136.96M | 134.78M | 133.24M | 131.16M |
| Cash flow statement | |||||
| Operating cash flow | -$391.78M | -$446.35M | -$778.78M | $1.66B | -$47.59M |
| Capital expenditure | $4.83M | $7.30M | $21.57M | $68.01M | $21.82M |
| Free cash flow | -$396.61M | -$453.65M | -$800.36M | $1.60B | -$69.41M |
| Investing cash flow | $310.37M | $499.37M | $164.63M | -$1.19B | -$140.81M |
| Financing cash flow | $3.79M | $4.39M | $7.48M | $34.76M | $100.33M |
| Depreciation & amortization | $11.68M | $14.56M | $19.45M | $6.78M | $5.28M |
| Stock-based compensation | $49.07M | $78.46M | $111.32M | $102.08M | $83.78M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.